House Energy and Commerce Committee leaders yesterday sent letters to nine contract pharmacies that participate in the 340B drug savings program requesting information about their participation in the program. The letters sought information on contracting practices; the distance between covered entities and contract pharmacies; to what degree contract pharmacies prevent duplicate discounts or diversion in the program; and whether contract pharmacies ensure low-income uninsured patients do not face high drug costs despite the program’s discount. The letters follow a June Government Accountability Office report recommending that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B requirements.
 

Related News Articles

Headline
The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s…
Headline
President Trump today announced the first agreement with a major pharmaceutical company, Pfizer, to bring American drug prices in line with the lowest paid by…
Headline
The anticipated burdens on hospitals to comply with the Health Resources and Services Administration’s 340B Rebate Pilot Program far exceed the agency’s…
Headline
The U.S. District Court for the District of Maine today issued an order denying preliminary injunctions requested by AbbVie and Novartis in legal challenges…
Headline
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical…
Headline
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction…